Gross ME - Search Results

1

Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.

Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross ME, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Kani K, et al. Among authors: gross me. Mol Cancer Ther. 2012 May;11(5):1071-81. doi: 10.1158/1535-7163.MCT-11-0852. Epub 2012 Mar 12. Mol Cancer Ther. 2012. PMID: 22411897 Free PMC article.

2

Targeting the HER-kinase axis in cancer.

Gross ME, Shazer RL, Agus DB. Gross ME, et al. Semin Oncol. 2004 Feb;31(1 Suppl 3):9-20. doi: 10.1053/j.seminoncol.2004.01.005. Semin Oncol. 2004. PMID: 15052539 Review.

3

Update on HER-kinase-directed therapy in prostate cancer.

Gross ME, Jo S, Agus DB. Gross ME, et al. Clin Adv Hematol Oncol. 2004 Jan;2(1):53-6, 64. Clin Adv Hematol Oncol. 2004. PMID: 16163160 Review.

4

Ductal adenocarcinoma of the prostate.

Shazer RL, Luthringer D, Agus DB, Gross ME. Shazer RL, et al. Among authors: gross me. Clin Adv Hematol Oncol. 2004 Jun;2(6):393-5; discussion 396. Clin Adv Hematol Oncol. 2004. PMID: 16163211 No abstract available.

5

Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.

Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB. Shazer RL, et al. BJU Int. 2006 Apr;97(4):691-7. doi: 10.1111/j.1464-410X.2006.05974.x. BJU Int. 2006. PMID: 16536755 Clinical Trial.

6

Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.

Gross M, Top I, Laux I, Katz J, Curran J, Tindell C, Agus D. Gross M, et al. Clin Cancer Res. 2007 Apr 1;13(7):1979-86. doi: 10.1158/1078-0432.CCR-06-1156. Clin Cancer Res. 2007. PMID: 17404077

7

A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.

Gross M, Higano C, Pantuck A, Castellanos O, Green E, Nguyen K, Agus DB. Gross M, et al. BMC Cancer. 2007 Jul 27;7:142. doi: 10.1186/1471-2407-7-142. BMC Cancer. 2007. PMID: 17662137 Free PMC article. Clinical Trial.

8

Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping.

Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Christie KM, et al. Psychooncology. 2009 May;18(5):508-14. doi: 10.1002/pon.1420. Psychooncology. 2009. PMID: 18756584

9

Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling.

Mink SR, Hodge A, Agus DB, Jain A, Gross ME. Mink SR, et al. Among authors: gross me. Prostate. 2010 Aug;70(11):1201-10. doi: 10.1002/pros.21155. Prostate. 2010. PMID: 20564426

10

Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.

Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME. Jiang Y, et al. Among authors: gross me. Clin Chem. 2010 Sep;56(9):1492-5. doi: 10.1373/clinchem.2010.143297. Epub 2010 Jun 25. Clin Chem. 2010. PMID: 20581083 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters